For what its worth based on current prices, forget overvalued AI stocks the likes of PLTR , NVDA or AVGO

Instead buy the dip in pharma counters like GSK and MRCK. This is the time to invest now if you have not added - both counters are favorites in hedgefunds lists because of their sure upside potential. 

To add to that, GSK has received recent approvals and endorsements for new drug development.

GSK announced the US Food and Drug Administration, FDA, has accepted the New Drug Application, NDA, for gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action for the treatment of female adults and adolescents with uncomplicated urinary tract infections, uUTIs. The FDA has granted Priority Review for this application and assigned a Prescription Drug User Fee Act, PDUFA, action date of 26 March 2025. The NDA is supported by results from the phase III EAGLE-2 and EAGLE-3 trials. In these studies, gepotidacin demonstrated non-inferiority to nitrofurantoin, the current standard of care for uUTI, in female adults and adolescents with a confirmed uUTI and a uropathogen susceptible to nitrofurantoin.